Wei Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Zheng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
L Wang
Department of Gynaecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 shared publicationsLiang Wang
Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
2 shared publicationsD Hornung
Department of Obstetrics and Gynaecology, University Hospital, Tübingen, Germany
1 shared publicationJianhua Yang
Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
1 shared publicationLin Mu
Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
1 shared publicationQiong Zhang
Department of Gynecology, Second Affiliated Hospital, Zhejiang University, College of Medicine, Zhejiang Hangzhou, China
1 shared publication
Latest Publications
- 1 June 2010
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 38 (3) , 987-993
Differences in Mitochondrial Proteins in the Eutopic Endometrium of Patients with Adenomyosis and Endometriosis Identified Using Surface-enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Adenomyosis and endometriosis have a similar pathogenesis; indeed, adenomyosis has been considered by some as a variant of endometriosis (‘internal endometriosis’). This study aimed to detect differences in mitochondrial proteins in eutopic endometrial samples from women with adenomyosis (n = 13) and endometriosis (n = 24), and from control patients (n = 29) using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) protein chip technology. A total of 82 and 78 mitochondrial protein peaks were found in adenomyosis and endometriosis individuals, respectively. Of these, 14 were common to women with adenomyosis and women with endometriosis, although only one of these (mass-to-charge [m/z] ratio 3499) was significantly different between the adenomyosis and endometriosis groups. It is concluded that, compared with control patients, there are differences in the mitochondrial proteins isolated from the eutopic endometrium of patients with adenomyosis and those with endometriosis. Although the changes in mitochondrial proteins in eutopic endometrium from patients with adenomyosis and endometriosis were largely similar, significant differences were also detected. Further identification of these proteins and elucidation of the differences will help towards the differential diagnosis of adenomyosis and endometriosis and new therapeutic approaches.
- 1 June 2010
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 38 (3) , 987-993
Differences in Mitochondrial Proteins in the Eutopic Endometrium of Patients with Adenomyosis and Endometriosis Identified Using Surface-enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Adenomyosis and endometriosis have a similar pathogenesis; indeed, adenomyosis has been considered by some as a variant of endometriosis (‘internal endometriosis’). This study aimed to detect differences in mitochondrial proteins in eutopic endometrial samples from women with adenomyosis (n = 13) and endometriosis (n = 24), and from control patients (n = 29) using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) protein chip technology. A total of 82 and 78 mitochondrial protein peaks were found in adenomyosis and endometriosis individuals, respectively. Of these, 14 were common to women with adenomyosis and women with endometriosis, although only one of these (mass-to-charge [m/z] ratio 3499) was significantly different between the adenomyosis and endometriosis groups. It is concluded that, compared with control patients, there are differences in the mitochondrial proteins isolated from the eutopic endometrium of patients with adenomyosis and those with endometriosis. Although the changes in mitochondrial proteins in eutopic endometrium from patients with adenomyosis and endometriosis were largely similar, significant differences were also detected. Further identification of these proteins and elucidation of the differences will help towards the differential diagnosis of adenomyosis and endometriosis and new therapeutic approaches.
- 21 February 2008
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 101 (2) , 161-165
Focal adhesion kinase expression in ovarian endometriosis
- 21 February 2008
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 101 (2) , 161-165
Focal adhesion kinase expression in ovarian endometriosis
- 22 August 2006
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 95 (2) , 177-178
Surface electromyography of pelvic floor muscles in stress urinary incontinence
- 22 August 2006
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 95 (2) , 177-178
Surface electromyography of pelvic floor muscles in stress urinary incontinence
- Open Access
- 1 May 2006
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 34 (3) , 284-290
Expression of Monocyte Chemotactic Protein-1 in Human Endometrial Cancer Cells and the Effect of Treatment with Tamoxifen or Buserelin
Monocyte chemotactic protein-1 (MCP-1) is an important determinant of macrophage infiltration in tumours. This study investigated the effect of tamoxifen and the gonadotrophin-releasing hormone agonist buserelin on MCP-1 in the human endometrial cancer cell line EFE-184. Reverse transcription polymerase chain reaction and Western blot analysis were used to determine MCP-1 mRNA and protein expression, respectively. Immunoreactive MCP-1 in the cell culture media was quantified by enzyme-linked immunosorbent assay. Tamoxifen inhibited MCP-1 mRNA and protein expression in endometrial cancer cells and inhibited MCP-1 secretion in a time- and dose-dependent manner at concentrations of 10−7 to 10−5 M. Buserelin had no significant effect on MCP-1 mRNA and protein expression. These results suggest that tamoxifen directly inhibits the expression of MCP-1 in this cell line by blocking the MCP-1 signalling pathways. These findings may contribute to the understanding of the mechanisms underlying the different effects of tamoxifen and gonadotrophin-releasing hormone agonists in the treatment of endometrial cancer.
- 1 May 2006
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 34 (3) , 284-290
Open AccessExpression of Monocyte Chemotactic Protein-1 in Human Endometrial Cancer Cells and the Effect of Treatment with Tamoxifen or Buserelin
Monocyte chemotactic protein-1 (MCP-1) is an important determinant of macrophage infiltration in tumours. This study investigated the effect of tamoxifen and the gonadotrophin-releasing hormone agonist buserelin on MCP-1 in the human endometrial cancer cell line EFE-184. Reverse transcription polymerase chain reaction and Western blot analysis were used to determine MCP-1 mRNA and protein expression, respectively. Immunoreactive MCP-1 in the cell culture media was quantified by enzyme-linked immunosorbent assay. Tamoxifen inhibited MCP-1 mRNA and protein expression in endometrial cancer cells and inhibited MCP-1 secretion in a time- and dose-dependent manner at concentrations of 10−7 to 10−5 M. Buserelin had no significant effect on MCP-1 mRNA and protein expression. These results suggest that tamoxifen directly inhibits the expression of MCP-1 in this cell line by blocking the MCP-1 signalling pathways. These findings may contribute to the understanding of the mechanisms underlying the different effects of tamoxifen and gonadotrophin-releasing hormone agonists in the treatment of endometrial cancer.